patients participating in clinical trials of other drugs; pregnant or lactating women; alt / ast> 5 times uln, or neutrophils <0.5 * 109 / l, or platelets less than 50 * 109 / l; expected survival time is less than 1 week; a clear diagnosis of rheumatism-related diseases; long-term oral anti-rejection drugs or immunomodulatory drugs; patients hypersensitive to nk cells and their preservation solution.

patients participating in clinical trials of other drugs; pregnant or lactating women; alt / ast> 5 times uln, or neutrophils <0.5 * 109 / l, or platelets less than 50 * 109 / l; expected survival time is less than 1 week; a clear diagnosis of rheumatism-related diseases; long-term oral anti-rejection drugs or immunomodulatory drugs; patients hypersensitive to nk cells and their preservation solution.

1. patients participating in clinical trials of other drugs; 2. pregnant or lactating women; 3. alt / ast> 5 times uln, or neutrophils <0.5 * 109 / l, or platelets less than 50 * 109 / l; 4. expected survival time is less than 1 week; 5. a clear diagnosis of rheumatism-related diseases; 6. long-term oral anti-rejection drugs or immunomodulatory drugs; 7. patients hypersensitive to nk cells and their preservation solution.

1. patients participating in clinical trials of other drugs; 2. pregnant or lactating women; 3. alt / ast> 5 times uln, or neutrophils <0.5 * 109 / l, or platelets less than 50 * 109 / l; 4. expected survival time is less than 1 week; 5. a clear diagnosis of rheumatism-related diseases; 6. long-term oral anti-rejection drugs or immunomodulatory drugs; 7. patients hypersensitive to nk cells and their preservation solution.